[Federal Register Volume 77, Number 36 (Thursday, February 23, 2012)]
[Notices]
[Pages 10755-10756]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-4139]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0001]


Request for Nominations for Voting Members on a Public Advisory 
Committee; Risk Communication Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is requesting 
nominations for members to serve on the Risk Communication Advisory 
Committee, Office of Planning, Office of Policy and Planning, Office of 
the Commissioner.
    FDA has a special interest in ensuring that women, minority groups, 
and individuals with disabilities are adequately represented on 
advisory committees and, therefore, encourages nominations of qualified 
candidates from these groups.

DATES: Nominations received on or before April 23, 2012 will be given 
first consideration for membership on the Risk Communication Advisory 
Committee. Nominations received after April 23, 2012 will be considered 
for nomination to the committee as later vacancies occur.

ADDRESSES: All nominations for membership should be sent electronically 
to <a href="/cdn-cgi/l/email-protection#c2a1b482ada1eca4a6a3eca5adb4"><span class="__cf_email__" data-cfemail="bbd8cdfbd4d895dddfda95dcd4cd">[email protected]</span></a> or by mail to the Advisory Committee Oversight and 
Management Staff, Food and Drug Administration, 10903 New Hampshire 
Ave., Bldg. 32, rm. 5103, Silver Spring, MD 20993-0002.

FOR FURTHER INFORMATION CONTACT: Regarding all nomination questions for 
membership, the primary contact is: Lee L. Zwanziger, Risk 
Communication Staff, Office of Planning, Office of Policy and Planning, 
Office of the Commissioner, Food and Drug Administration, 10903 New 
Hampshire Ave., Silver Spring, MD 20993, 301-796-9151, Fax: 301-847-
8611, <a href="/cdn-cgi/l/email-protection#4517060406050301046b0d0d166b020a13"><span class="__cf_email__" data-cfemail="80d2c3c1c3c0c6c4c1aec8c8d3aec7cfd6">[email protected]</span></a>.
    Information about becoming a member on an FDA advisory committee 
can also be obtained by visiting FDA's Web site by using the following 
link: http://www.fda.gov/AdvisoryCommittees/default.htm.

SUPPLEMENTARY INFORMATION: FDA is requesting nomination for voting 
members on the Risk Communication Advisory Committee.

I. General Description of the Committee Duties

    The Risk Communication Advisory Committee advises the Commissioner 
of Food and Drugs or designee on methods to effectively communicate 
risks associated with products regulated by the Food and Drug 
Administration and in discharging responsibilities as they relate to 
helping to ensure safe and effective drugs for human use and any other 
product for which the Food and Drug Administration has regulatory 
responsibility.
    The Committee reviews and evaluates strategies and programs 
designed to communicate with the public about the risks and benefits of 
FDA-regulated products so as to facilitate optimal use of these 
products. The Committee also reviews and evaluates research relevant to 
such communication to the public by both FDA and other entities. It 
also facilitates interactively sharing risk and benefit information 
with the public to enable people to make informed independent judgments 
about use of FDA-regulated products.

II. Criteria for Voting Members

    The Committee consists of a core of 15 voting members including the 
Chair. Members and the Chair are selected by the Commissioner or 
designee from among authorities knowledgeable in fields such as social 
marketing, health literacy, and other relevant areas. Members will 
include experts on risk communication, experts on emerging postmarket 
drug risks and individuals knowledgeable about and experienced in the 
work of patient, consumer, and health professional organizations. 
Almost all non-Federal members of this committee serve as Special 
Government Employees. Some members will be selected to provide 
experiential insight on the communication needs of the various groups 
who use FDA-regulated products. The latter may include patients and 
patients' family members, health professionals, communicators in 
health, medicine and science, and persons affiliated with consumer, 
specific disease, or patient safety advocacy groups. Members will be 
invited to serve for terms of up to 4 years.

[[Page 10756]]

III. Nomination Procedures

    Any interested person may nominate one or more qualified 
individuals for membership on the advisory committee. Self-nominations 
are also accepted. Nominations must include a current, complete 
r[eacute]sum[eacute] or curriculum vitae for each nominee, including 
current business address and/or home address, telephone number, and 
email address if available. Nominations must also specify the advisory 
committee for which the nominee is recommended. Nominations must also 
acknowledge that the nominee is aware of the nomination unless self-
nominated. FDA will ask potential candidates to provide detailed 
information concerning such matters related to financial holdings, 
employment, and research grants and/or contracts to permit evaluation 
of possible sources of conflicts of interest.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

    Dated: February 16, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2012-4139 Filed 2-22-12; 8:45 am]
BILLING CODE 4160-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>